非洲疟疾流行区疟疾疫苗RTS,S/AS01成本效果的国家特异性预测
研究使用恶性疟原虫流行病学模型集合,在43个国家评估RTS,S/AS01疫苗加入常规疟疾控制后的健康获益与成本效果。每剂5美元时每名全程接种儿童项目成本平均39.8美元,每避免1个DALY的中位成本效果比为188美元(范围78–22448美元)。
要点
- 每剂5美元时每名全程接种儿童项目成本平均39.8美元,每避免1个DALY中位成本效果比188美元(范围78–22448美元)。
- 2–10岁儿童寄生虫患病率≥10%的地区,成本效果比降至136美元(范围116–220美元),低约三分之一。
核心结论
- RTS,S/AS01有潜力大幅降低非洲儿童疟疾负担,在价格、覆盖率和疫苗特性假设下加入常规疟疾控制具有高度成本效果。
- 实施决策还需进一步考虑扩大现有控制规划的可行性及按接种程序覆盖高危儿童的操作限制。
研究设计与样本
- 使用恶性疟原虫流行病学模型集合,在43个国家评估RTS,S/AS01的影响与成本效果。
- 依据3期试验32个月随访数据,按各国疟原虫患病率、控制干预覆盖率和免疫覆盖评估疫苗效果。
- 评估四剂程序:第1剂6月龄接种,第2、3剂在9月龄前,第4剂27月龄接种。
- 围绕疫苗特性、传播和经济投入进行敏感性分析。
主要发现
- 每10万名全程接种儿童平均避免18413个DALY(各国中位估计范围156–40054),差异主要由传播强度不同驱动。
- 每剂5美元时,每名全程接种儿童项目成本平均39.8美元,每避免1个DALY的中位成本效果比为188美元(范围78–22448美元)。
- 2–10岁儿童寄生虫患病率≥10%的地区,成本效果比低约三分之一,为136美元(范围116–220美元)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: RTS,S/AS01 is a safe and moderately efficacious vaccine considered for implementation in endemic Africa. Model predictions of impact and cost-effectiveness of this new intervention could aid in country adoption decisions. METHODS: The impact of RTS,S was assessed in 43 countries using an ensemble of models of Plasmodium falciparum epidemiology. Informed by the 32months follow-up data from the phase 3 trial, vaccine effectiveness was evaluated at country levels of malaria parasite prevalence, coverage of control interventions and immunization. Benefits and costs of the program incremental to routine malaria control were evaluated for a four dose schedule: first dose administered at six months, second and third - before 9months, and fourth dose at 27months of age. Sensitivity analyses around vaccine properties, transmission, and economic inputs were conducted. RESULTS: If implemented in all 43 countries the vaccine has the potential to avert 123 (117;129) million malaria episodes over the first 10years. Burden averted averages 18,413 (range of country median estimates 156-40,054) DALYs per 100,000 fully vaccinated children with much variation across settings primarily driven by differences in transmission intensity. At a price of $5 per dose program costs average $39.8 per fully vaccinated child with a median cost-effectiveness ratio of $188 (range $78-$22,448) per DALY averted; the ratio is lower by one third - $136 (range $116-$220) - in settings where parasite prevalence in children aged 2-10years is at or above 10%. CONCLUSION: RTS,S/AS01has the potential to substantially reduce malaria burden in children across Africa. Conditional on assumptions on price, coverage, and vaccine properties, adding RTS,S to routine malaria control interventions would be highly cost-effective. Implementation decisions will need to further consider feasibility of scaling up existing control programs, and operational constraints in reaching children at risk with the schedule.
引用
- Galactionova K, Tediosi F, Camponovo F, et al. Country specific predictions of the cost-effectiveness of malaria vaccine RTS,S/AS01 in endemic Africa. Vaccine. 2016. PMID: 27890400. doi:10.1016/j.vaccine.2016.11.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。